Search for new antitumor compounds among n-glycoside indolo[2,3-a]carbazole derivatives
- 作者: Kiseleva M.1, Smirnova Z.1, Borisova L.1, Kubasova I.1, Ektova L.1, Miniker T.1, Plikhtiak I.1, Medvedeva L.1, Eremina V.1, Tikhonova N.1
-
隶属关系:
- N.N. Blokhin Russian Cancer Research Center
- 期: 卷 20, 编号 1 (2015)
- 页面: 33-37
- 栏目: Articles
- URL: https://journals.rcsi.science/1028-9984/article/view/40133
- DOI: https://doi.org/10.17816/onco40133
- ID: 40133
如何引用文章
全文:
详细
作者简介
Marina Kiseleva
N.N. Blokhin Russian Cancer Research Center
Email: marina-kiselyova@mail.ru
MD 115478, Moscow, Russian Federation
Z. Smirnova
N.N. Blokhin Russian Cancer Research Center115478, Moscow, Russian Federation
L. Borisova
N.N. Blokhin Russian Cancer Research Center115478, Moscow, Russian Federation
I. Kubasova
N.N. Blokhin Russian Cancer Research Center115478, Moscow, Russian Federation
L. Ektova
N.N. Blokhin Russian Cancer Research Center115478, Moscow, Russian Federation
T. Miniker
N.N. Blokhin Russian Cancer Research Center115478, Moscow, Russian Federation
I. Plikhtiak
N.N. Blokhin Russian Cancer Research Center115478, Moscow, Russian Federation
L. Medvedeva
N.N. Blokhin Russian Cancer Research Center115478, Moscow, Russian Federation
V. Eremina
N.N. Blokhin Russian Cancer Research Center115478, Moscow, Russian Federation
N. Tikhonova
N.N. Blokhin Russian Cancer Research Center115478, Moscow, Russian Federation
参考
- Shtil A.A. Signal transduction pathways and transcriptional mechanisms as targets for prevention of emergence of multidrug resistance in human cancer cells (invited review). Cur. Drug Targets. 2001; 2: 57-77.
- Bridges J.A. Chemical inhibitors of protein kinases. Chem. Rev. 2001; 101: 2541-71.
- Sordet O., Khan Q.A., Kohn K.W., Pommier Y. Apoptosis induced by topoisomerase inhibitors. Curr. Med. Chem. Anticancer Agents. 2003; 3 (4): 271-90.
- Pindur U., Kim Y-S., Meharbani F. Advances in indolo 2,3-a. carbazole chemistry: design and synthesis of protein kinase C and topoisomerase I inhibitors. Cur. Med. Chem. 1999; 6: 29-68.
- Kleinschrot J., Hartenstein J., Rudolf C., Schachtele C. Novel indolocarbazole protein kinase C inhibitors with improved biochemical and physicochemical properties. Bio-org. Med. Chem. Lett. 1995; 5: 55-60.
- Meng L.-H., Liao Z.-Y., Pommier Y. Non-camptothecin DNK topoisomerase I inhibitors in cancer therapy. Curr. Top. Med. Chem. 2003; 3 (3): 305-20.
- Bush J.A., Long B.H., Catino J.J., Bradner W.T. Production and biological activity of rebeccamycin, a novel antitumor agent. J. Antibiot. 1987; 40: 668-78.
- Yoshinari T., Yamada A., Uemura D., Nomura K., Arakawa H., Kojiri K. et al. Induction of topoisomerase I mediated DNA cleavage by a new indolocarbazole ED-1101. Cancer Res. 1993; 53: 490-4.
- Schwandt A., Mekhail T., Halmos B. et al. Phase-II trial of rebeccamycin analog, a dual topoisomerase-I and -II inhibitor, in relapsed “sensitive» small cell lung cancer. J. Thorac. Oncol. 2012; 7(4): 751-4.
- Prudhomme M. Biological targets of antitumor indolocarbazoles bearing a sugar moiety. Curr. Med. Chem. Anti-cancer Agents. 2004; 4: 509-21.
- Колс Ян. Применение Мидостаурина для лечения желудочно-кишечных стромальных опухолей. Патент РФ № 2410098, 2011.
- Мельник С.Я. Синтез и изучение гликозидов, производных бисиндола и родственных индоло[2,3-а]карбазолов. В кн.: Давыдов М.И., Барышников А.Ю., ред. В кн.: Экспериментальная онкология на рубеже веков. М.; 2003: 281-93.
- Методические рекомендации по доклиническому изучению противоопухолевой активности лекарственных средств. В кн. Руководство по проведению доклинических исследований лекарственных средств. Часть первая. М.: Гриф и К.; 2012: 642-56.
- Софьина З.П., Сыркин А.Б. (СССР), Голдин А., Кляйн А. (США), ред. Экспериментальная оценка противоопухолевых препаратов в СССР и США. М.: Медицина; 1979.